Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2025-08-27 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "华兰生物工程股份有限公司2025 年半年度报告全文" which translates to "Hualan Biological Engineering Co., Ltd. 2025 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company business overview, product descriptions, and operational details for the half-year period ending June 30, 2025. The document includes comprehensive financial statements and substantive financial data, not just an announcement or summary. It is a full interim/quarterly report covering a period shorter than a full fiscal year, consistent with the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-27 Chinese
2025年半年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement regarding the company's 2025 half-year profit distribution plan, including dividend amounts, rationale, and financial data from the half-year financial report. It discusses the board meeting resolutions, dividend policy, and financial performance but does not contain the full half-year financial report itself. The document length is 2515 characters, which is relatively short and typical for an announcement rather than a full interim report. It explicitly states that the profit distribution plan is subject to shareholder meeting approval and provides detailed dividend information. This fits the profile of a Notice of Dividend Amount (DIV) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2025-08-27 Chinese
半年报董事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the company's ninth board of directors second meeting, including approval of the 2025 semi-annual report and profit distribution plan. It contains no actual financial statements or detailed financial data but rather summarizes decisions and voting results. The document also announces the scheduling of a shareholders meeting. The length is short (1332 characters), and it serves as a formal notice of board decisions rather than the report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about board meeting resolutions and related corporate governance matters, not the full interim report or a detailed management report.
2025-08-27 Chinese
关于公司控股子公司取得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its subsidiary receiving approval for a drug clinical trial from a regulatory authority. It contains no financial data, no report or presentation, and is not a certification or voting result. The document is short (1041 characters) and serves as a notification of a regulatory event related to drug development. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-08-13 Chinese
职工代表大会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement regarding the election of a staff representative director to the company's board. It includes biographical details and compliance statements but does not contain financial data, audit information, or report content. It is not a full report, earnings release, or regulatory filing of financial results. It is an announcement related to board/management changes, specifically the election of a new board member. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a report publication or regulatory filing.
2025-07-08 Chinese
关于董事会完成换届选举暨聘任高级管理人员等相关人员的公告
Board/Management Information Classification · 95% confidence The document is an announcement from 华兰生物工程股份有限公司 regarding the completion of the board of directors' re-election and the appointment of senior management personnel. It details the election results, committee appointments, and biographies of the newly appointed executives and securities affairs representatives. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board and senior management, which fits the category of Board/Management Information (MANG). The document length is 4687 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or other types of filings. Therefore, the appropriate classification is MANG with high confidence.
2025-07-08 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.